Company intelligence / Profile preview

VaccGen International

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

VaccGen International is a clinical-stage biotechnology company focused on the development of a therapeutic vaccine for HIV-1. The company's lead candidate, VGX-101, is a recombinant protein vaccine designed to elicit a broad immune response against the HIV-1 envelope glycoprotein. VaccGen aims to provide a functional cure or a long-term management solution for individuals living with HIV by enhancing the body's natural ability to control viral replication. The company is currently advancing its clinical programs to evaluate the safety and immunogenicity of its vaccine candidates in human trials.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on VaccGen International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VaccGen International.

Explore the full profile